Related Experiment Video
Updated: Jan 19, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
Yu Yu1, Yohan Suryo Rahmanto1, Yao-An Shen1
1Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medical Institutions, Baltimore, MD 21231, United States of America; Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21205, United States of America.
Background:
Spleen tyrosine kinase (SYK) is frequently upregulated in recurrent ovarian carcinomas, for which effective therapy is urgently needed. SYK phosphorylates several substrates, but their translational implications remain unclear. Here, we show that SYK interacts with EGFR and ERBB2, and directly enhances their phosphorylation.
Methods:
We used immunohistochemistry and immunoblotting to assess SYK and EGFR phosphorylation in ovarian serous carcinomas. Association with survival was determined by Kaplan-Meier analysis and the log-rank test. To study its role in EGFR signaling, SYK activity was modulated using a small molecule inhibitor, a syngeneic knockout, and an active kinase inducible system. We applied RNA-seq and phosphoproteomic mass spectrometry to investigate the SYK-regulated EGF-induced transcriptome and downstream substrates.
Findings:
Induced expression of constitutively active SYK130E reduced cellular response to EGFR/ERBB2 inhibitor, lapatinib. Expression of EGFRWT, but not SYK non-phosphorylatable EGFR3F mutant, resulted in paclitaxel resistance, a phenotype characteristic to SYK active ovarian cancers. In tumor xenografts, SYK inhibitor reduces phosphorylation of EGFR substrates. Compared to SYKWT cells, SYKKO cells have an attenuated EGFR/ERBB2-transcriptional activity and responsiveness to EGF-induced transcription. In ovarian cancer tissues, pSYK (Y525/526) levels showed a positive correlation with pEGFR (Y1187). Intense immunoreactivity of pSYK (Y525/526) correlated with poor overall survival in ovarian cancer patients.
Interpretation:
These findings indicate that SYK activity positively modulates the EGFR pathway, providing a biological foundation for co-targeting SYK and EGFR. FUND: Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, NIH/NCI, Ovarian Cancer Research Foundation Alliance, HERA Women's Cancer Foundation and Roseman Foundation. Funders had no role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript and eventually in the decision to submit the manuscript.
Insights
Spleen tyrosine kinase (SYK) enhances epidermal growth factor receptor (EGFR) and ERBB2 phosphorylation in ovarian cancer. Targeting both SYK and EGFR may offer new therapeutic strategies for patients with recurrent ovarian carcinomas.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Spleen tyrosine kinase (SYK) is upregulated in recurrent ovarian carcinomas, necessitating novel therapeutic approaches.
- SYK's substrates and their clinical relevance in ovarian cancer remain largely undefined.
- This study investigates the role of SYK in modulating receptor tyrosine kinase signaling pathways.
Purpose of the Study:
- To elucidate the interaction between SYK, EGFR, and ERBB2 in ovarian cancer.
- To determine the functional consequences of SYK-mediated phosphorylation of EGFR and ERBB2.
- To explore the therapeutic potential of co-targeting SYK and EGFR/ERBB2.
Main Methods:
- Immunohistochemistry and immunoblotting to detect SYK and EGFR phosphorylation in ovarian serous carcinomas.
- Kaplan-Meier analysis and log-rank test to assess survival associations.
- Modulation of SYK activity using small molecule inhibitors, gene knockout, and inducible systems.
- RNA-sequencing and phosphoproteomic mass spectrometry to identify SYK-regulated downstream targets.
Main Results:
- SYK activity enhances EGFR and ERBB2 phosphorylation, reducing sensitivity to lapatinib.
- EGFR activation, but not SYK-mutant EGFR, confers paclitaxel resistance, a phenotype linked to SYK activity in ovarian cancers.
- SYK inhibition decreased EGFR substrate phosphorylation in xenografts.
- SYK knockout cells exhibited attenuated EGFR/ERBB2 transcriptional activity and EGF responsiveness.
- Increased pSYK levels correlated with pEGFR and poor patient survival in ovarian cancer tissues.
Conclusions:
- SYK positively modulates the EGFR pathway in ovarian cancer.
- SYK activity is associated with poor prognosis and confers resistance to standard therapies.
- Co-targeting SYK and EGFR presents a promising therapeutic strategy for ovarian cancer.
Related Concept Videos
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Receptor Tyrosine Kinases
09:16Studying the Stoichiometry of Epidermal Growth Factor Receptor in Intact Cells using Correlative Microscopy
07:09Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:36Systems Biology of Metabolic Regulation by Estrogen Receptor Signaling in Breast Cancer

